Form 4: Cumberland Pharmaceuticals Director James Jones Acquires Shares Through Pre-Arranged Trading Plan

Director James Jones of Cumberland Pharmaceuticals has acquired shares through a pre-arranged trading plan, increasing his holdings.

Summary

• James Jones, a director at Cumberland Pharmaceuticals, has been acquiring shares of the company's common stock.
• These purchases were made through a pre-arranged Rule 10b5-1 trading plan adopted on March 13, 2024.
• The transactions occurred between December 2, 2024, and December 20, 2024.
• A total of 70 shares were purchased on most days, with some days having purchases of 65, 49, 40, or 32 shares.
• The purchase prices ranged from $1.20 to $2.48 per share.
• Following these transactions, Mr. Jones's total direct holdings increased from 39,447 to 40,146 shares.

Sentiment

Score: 6

Explanation: The document reflects routine insider trading activity under a pre-arranged plan, which is neither particularly positive nor negative. It indicates a director's continued investment in the company, which is generally a neutral to slightly positive signal.

Positives

• The director's continued investment in the company may signal confidence in its future prospects.
• The purchases were made through a pre-arranged trading plan, indicating a structured and consistent approach to share acquisition.

Industry Context

This is a standard SEC Form 4 filing, which is common for corporate insiders who trade their company's stock. It provides transparency into the trading activities of company directors.

Comparison to Industry Standards

• SEC Form 4 filings are a standard practice for publicly traded companies in the United States.
• The trading activity reported is consistent with what is expected from directors who have pre-arranged trading plans.
• The range of prices paid is within the normal fluctuations of the stock price.

Stakeholder Impact

• The increased holdings of a director may be viewed positively by shareholders, indicating confidence in the company's future.

Key Dates

Keywords

Cumberland Pharmaceuticals, James Jones, share acquisition, Rule 10b5-1, insider trading, director, stock purchase